[DOI] [PMC free article] [PubMed] [Google Scholar] 119.Klotsman M, Adin CA, Anderson WH, Gilor C
We examine the role of receptor binding kinetics and -arrestin-biased signaling in the observed trafficking profiles, identifying a linked set of agonist characteristics optimally suited for insulin secretion, not shared by GLP-1R agonists in the current clinical use
According to CareEdge Ratings, the GLP-1 market, valued at around 1,0001,200 crore in 2025, is expected to grow to 4,5005,000 crore by 2030, with patent expiry acting as a key driver
2024 Aug 28;16(17):2886
Simultaneous use risks treatment abandonment due to intolerable side effects, defeating the therapeutic goal
However, tirzepatide causes more pronounced gastroparesis than semaglutide